Citi Pharma Limited

Citi Pharma Limited is a prominent Pakistan-based pharmaceutical company primarily engaged in the manufacturing and sale of Active Pharmaceutical Ingredients (APIs), finished dosage forms, and botanical products. Established in 2012 and headquartered in Lahore, the company has grown into one of the largest API manufacturers in Pakistan, maintaining a significant presence in both local and international markets. Its portfolio spans various therapeutic categories, including antibiotics, cardiovascular, anti-diabetic, and analgesic treatments. In recent years, the company has pursued a strategy of aggressive diversification and vertical integration. This includes moving into direct marketing, establishing a dedicated Bioequivalence & Research Center, and expanding into biotechnology areas such as insulin, vaccines, and monoclonal antibodies. Furthermore, Citi Pharma has diversified beyond its core pharmaceutical business by entering the real estate sector through a new REIT management subsidiary and planning an IPO for its veterinary pharmaceutical subsidiary, Citi Veterinary Pharma Limited.